Takeda Pharmaceutical Co ADR (TAK) — Titan Protect Analysis

TAK

Takeda Pharmaceutical Co ADR

Healthcare · ·

$15.60

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$47.3B

Total market value of the company

Trailing P/E

40.50

Expensive — high growth expected

Forward P/E

28.27

Based on estimated future earnings — lower means cheaper

Rev Growth

+3.9%

Year-over-year revenue change

Profit Margin

4.3%

How much profit the company keeps from each dollar of revenue

ROE

2.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.71

+33% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About Takeda Pharmaceutical Co ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombi

https://www.takeda.com

Country: Japan Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.553

Good returns relative to risk taken

Kelly Fraction

0.0238

Modest edge detected — smaller position warranted

Calmar Ratio

0.472

Drawdown risk outweighs the returns — higher risk profile

Annual Return

9.5%

Historical annualised return based on price data

Max Drawdown

-20.1%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.10

Very low correlation to market moves

52W High

$18.90

17% below the year high

52W Low

$12.99

20% above the year low

Avg Volume

2,981,595

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

436.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.37

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

70.14

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

65.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

3.1%

Profit from core operations before interest and tax

Free Cash Flow

$356.6B

Positive — the business generates more cash than it spends

Revenue (TTM)

$4.5T

Total revenue over the last 12 months

Net Income

$191.8B

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$21.71

Target Median

$20.71

Target Low

$18.60

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
21 Apr2026	Thomas Kean Jr	Republican	sell	1K–15K
2026-04-21	Thomas Kean Jr	Republican	Sale	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go